Skip to main content
Epocrates Online
Contact us
Explore features
Reach clinicians
Buy now
By
vgreene
, 23 January, 2015
Severe:<sup>2,4</sup> I&D [S/H], C&S, and:
By
vgreene
, 23 January, 2015
Clindamycin<sup>5</sup> 600 mg IV q8h or 300-450 mg PO qid [S/L]
By
vgreene
, 23 January, 2015
Cefazolin<sup>3</sup> 1 g IV q8h [S/L]
By
vgreene
, 23 January, 2015
Oxacillin<sup>9</sup> 1-2 g IV q4h [S/L]
By
vgreene
, 23 January, 2015
Oxacillin<sup>3</sup> 1-2 g IV q4h [S/L]
By
vgreene
, 23 January, 2015
Nafcillin<sup>3</sup> 1-2 g IV q4h [S/L]
By
vgreene
, 23 January, 2015
Ceftaroline 600 mg IV q12h [S/L]
By
vgreene
, 23 January, 2015
Telavancin [S/L]
By
vgreene
, 23 January, 2015
Linezolid 600 mg IV/PO q12h [S/L]
By
vgreene
, 23 January, 2015
Daptomycin 4 mg/kg IV q24h [S/L]
Pagination
First page
Previous page
…
Page
3973
Page
3974
Page
3975
Page
3976
Current page
3977
Page
3978
Page
3979
Page
3980
Page
3981
…
Next page
Last page
About Us
Company Overview
Media Relations
Contact
Editorial Policy
Editorial Process
Third-Party Sponsorship Policy
athenahealth
Products
Core Products
Mobile CME
Product Licenses
Business Solutions
Pharma
Market Research
Institutions
Support
Support Center
Install
My Account
Stay Connected
Facebook
Twitter
YouTube